Investigation Report on China Piperacillin Sodium and Tazobactam Sodium Market [2010-2019]
- Submitted by: SarahDavis12
- Views: 47
- Category: Other
- Date Submitted: 12/17/2015 10:01 PM
- Pages: 3
- Report this Essay
Dec., 18, 2015, Mumbai, India: Market Reports on China presents the report, on “Investigation Report on China Piperacillin Sodium and Tazobactam Sodium Market [2010-2019]”. Piperacillin sodium and tazobactam sodium has been widely applied in the clinic with efficacy being confirmed by the randomized controlled trials conducted by multiple centers at home and abroad.
Piperacillin sodium and tazobactam sodium is the compound drug of piperacillin sodium and tazobactam sodium, the former being semi-synthesized broad-spectrum penicillin while the latter being β-lactamase inhibitor. "http://www.marketreportsonchina.com/life-sciences-market-research-reports-16505/investigation-china-piperacillin-tazobactam-sodium.html" Tazobactam sodium can prevent piperacillin from the β-lactamase hydrolysis of some drug-resistant bacteria so as to maintain piperacillins antimicrobial activity or even expand its spectrum. The injection product of Piperacillin sodium and tazobactam sodium (piperacillin sodium and tazobactam sodium for injection) is often used in the clinic.
Since its first marketing in France in 1992, piperacillin sodium and tazobactam sodium has entered the US, mainland Europe, Japan and Singapore. According to market survey, piperacillin sodium and tazobactam sodium develops fast after entering China in Oct. 1998, annual sales value rising from less than CNY 2 million in 2005 to CNY 1.064 billion in 2014 and CAGR during this period reaching 22.2%.
Wyeth Pharmaceutical Co., Ltd (US), Qilu Pharmaceutical Co., Ltd, North China Pharmaceutical Group Corporation, Zhejiang Anglikang Pharmaceutical Co., Ltd and United Laboratories occupy the majority of the Chinese market, among which Wyeth Pharmaceutical Co., Ltd (US) has the largest market share of about 36% for sales value in 2014.
Piperacillin sodium and tazobactam sodium has been widely applied in the clinic with efficacy being confirmed by the randomized controlled trials conducted by multiple centers at home...
Piperacillin sodium and tazobactam sodium is the compound drug of piperacillin sodium and tazobactam sodium, the former being semi-synthesized broad-spectrum penicillin while the latter being β-lactamase inhibitor. "http://www.marketreportsonchina.com/life-sciences-market-research-reports-16505/investigation-china-piperacillin-tazobactam-sodium.html" Tazobactam sodium can prevent piperacillin from the β-lactamase hydrolysis of some drug-resistant bacteria so as to maintain piperacillins antimicrobial activity or even expand its spectrum. The injection product of Piperacillin sodium and tazobactam sodium (piperacillin sodium and tazobactam sodium for injection) is often used in the clinic.
Since its first marketing in France in 1992, piperacillin sodium and tazobactam sodium has entered the US, mainland Europe, Japan and Singapore. According to market survey, piperacillin sodium and tazobactam sodium develops fast after entering China in Oct. 1998, annual sales value rising from less than CNY 2 million in 2005 to CNY 1.064 billion in 2014 and CAGR during this period reaching 22.2%.
Wyeth Pharmaceutical Co., Ltd (US), Qilu Pharmaceutical Co., Ltd, North China Pharmaceutical Group Corporation, Zhejiang Anglikang Pharmaceutical Co., Ltd and United Laboratories occupy the majority of the Chinese market, among which Wyeth Pharmaceutical Co., Ltd (US) has the largest market share of about 36% for sales value in 2014.
Piperacillin sodium and tazobactam sodium has been widely applied in the clinic with efficacy being confirmed by the randomized controlled trials conducted by multiple centers at home...